Get the latest news, insights, and market updates on ANAB (AnaptysBio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation
AnaptysBio (ANAB) just revealed that its Phase 2 trial for rosnilimab in moderate-to-severe ulcerative colitis is being discontinued because the treatment did not outperform placebo in reaching clinical or endoscopic remission goals. See our latest analysis for AnaptysBio. Even with the disappointment in ulcerative colitis, AnaptysBio’s momentum hasn’t slowed much in the bigger picture. The stock has notched a staggering 177% share price return year to date, showing strong investor interest,... Nov 20, 2025 - $ANAB
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at Week 12 does not support further development of rosnilimab in UC and trial will be discontinued, resulting in at least $10 million in savingsWill provide update in H1 2026 on advancement of rosnilimab in RA, which would be funded by strategic or other sources of capital without diluting our royaltie Nov 10, 2025 - $ANAB
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data for rosnilimab in rheumatoid arthritis featured as late-breaking oral presentation at ACR Convergence 2025Phase 1b initiated in celiac disease for ANB033, a CD122 antagonist; top-line Phase 1b data anticipated in Q4 2026GSK announced strong commercial performan Nov 4, 2025 - $ANAB
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen Immunology & Inflammation Summit, Virtual Format – Fireside chatDate and Time – Wednesday, Nov. 12, 2025 Nov 4, 2025 - $ANAB
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades
AnaptysBio (ANAB) just shared fresh Phase 2b results for rosnilimab in rheumatoid arthritis, showing that the drug’s benefits lasted well beyond initial treatment and deepened across 28 weeks, regardless of previous therapies. See our latest analysis for AnaptysBio. Momentum around AnaptysBio has been unmistakable, with a 14.4% jump in share price over the past month and an impressive 48% gain in the last three months. This performance has been fueled by optimism following their latest... Nov 1, 2025 - $ANAB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple